Well, we got that.
Ugh. Ugh, ugh, ugh, ugh.
I am, however, surprised at the bitter tone of sector journalists, aimed at Bishop et al. and FDA. Clinical trial participants are heroes, and informed consent of this extreme nature is countered by the chance for a durable, long-term remission.
FDA walks that line, and everyone at FDA would love to throw around the c word.
A better therapeutic window is needed, that is certain. May need to infuse cells in the presence of a modulator, and slowly release the brakes. Need transformation-specific antigens, and tools to recognize extremely "weak" ones. I'd go on, but my circa-2000 perspective and insights would show.
Not certain if blcm ever disclosed the start of this trial.....
clinicaltrials.gov |
